我們已在上線！進一步了解

Kestra Medical Technologies

KMTS

市值 US$16.2億

27.24 USD

-1.44

5.02%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

27.04

-0.20

0.73%

1天

-5.02%

5天

0.81%

1個月

13.12%

3個月

13.59%

6個月

33.46%

今年迄今

11.69%

1年

17.06%

5年

24.73%

10年

24.73%

關於： Kestra Medical Technologies Ltd is a commercial-stage wearable medical device and digital healthcare company focused on connected monitoring, therapeutic intervention, and data-driven clinical insights for cardiovascular disease. It has developed and is commercializing the Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. The platform is anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected. The platform also includes digital patient engagement and clinical workflow solutions.

員工： 443

醫療保健醫療器材與用品

新聞

正面

中性

負面

市場情緒 3個月

正面 15.4%

中性 53.8%

負面 30.8%

Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies

KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek's list of America's Greatest Mid-Market Companies 2026. Only 30 of the 100 honorees earned five stars, and Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating.

Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies

Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizon

Kestra Medical Technologies is transitioning into a high-growth, high-quality medtech platform with 60% YoY revenue growth and expanding gross margins. KMTS targets mid-70s gross margins within 2–3 years, driven by improved payer mix, scale, and supplier leverage, validating its unit economics story. Despite strong top-line momentum and raised FY27 guidance, profitability remains distant with a $44M net loss and $32M quarterly cash burn.

Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizon

Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures falling around 200 points on Tuesday.

Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript

Zacks Investment Research

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates

Kestra Medical Technologies, Ltd. (KMTS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.61.

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates

Kestra Medical Technologies Q1 Earnings Call Highlights

Kestra Medical Technologies NASDAQ: KMTS reported first-quarter fiscal 2027 revenue of $31 million, with President and Chief Executive Officer Brian Webster saying revenue rose 60% from a year earlier and advanced sequentially from the fourth quarter. The company raised its full-year revenue outlook to $141 million from a prior forecast of $137 million, representing expected growth of 48% over fiscal 2026.

Kestra Medical Technologies Q1 Earnings Call Highlights

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026.

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) will release its first earnings report after the closing bell on Monday, Sept.

Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Kestra Names Daniel Finney Vice President of Research & Development

KIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finney has been named Vice President of Research & Development and appointed to the company's executive leadership team.

Kestra Names Daniel Finney Vice President of Research & Development

Zacks Investment Research

Analysts Estimate Kestra Medical Technologies, Ltd. (KMTS) to Report a Decline in Earnings: What to Look Out for

Kestra Medical Technologies, Ltd. (KMTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Analysts Estimate Kestra Medical Technologies, Ltd. (KMTS) to Report a Decline in Earnings: What to Look Out for

查看新聞排名

價格圖表採用Lightweight Charts™實作